Latest Biochemical recurrence Stories
A new anti-cancer drug aimed at vitamin D receptors on cancer cells has prompted encouraging responses in the levels of PSA (prostate specific antigen) in men with prostate cancer that has become resistant to hormonal therapies.
A first-ever, long-term study of patients who underwent robot-assisted surgery to remove their cancerous prostates found that nearly 87 percent of them had no recurrence of the disease after five years.
Men who use statins to lower their cholesterol are 30 percent less likely to see their prostate cancer come back after surgery compared to men who do not use the drugs.
BETHESDA, Md., Dec. 4 /PRNewswire/ -- Drs. Neal Shore and E.
Prostate cancer patients who have a prostate-specific antigen (PSA) value of less than or equal to 1.5 at two years after external beam radiation therapy (EBRT) are less likely to have a cancer recurrence and cancer-related death.
Men whose prostate specific antigen (PSA) rise within 18 months of radiotherapy are more likely to develop spread and die of their disease.
A team of Northwestern University researchers, using an extremely sensitive tool based on nanotechnology, has detected previously undetectable levels of prostate-specific antigen (PSA) in patients who have undergone radical prostatectomy.
Italian researchers suggest using positron emission tomography and computer tomography with choline to detect recurring prostate cancer earlier.
A new study published in the September issue of The Journal of Nuclear Medicine shows that positron emission tomography (PET)/computer tomography (CT) scans with the imaging agent choline could detect recurring prostate cancer sooner than conventional imaging technologies in some patients who have had their prostates surgically removed.
The American Urological Association is urging U.S. men to decrease their risk of developing prostate cancer by managing their cholesterol. Two separate studies point out an association between cholesterol levels and prostate health risks.
- A trick or prank.